Cerebral malaria (CM) is one of the most lethal complications of *Plasmodium falciparum*malaria, responsible for a large fraction of the 1,238,000 (95% confidence interval: 929,000-1,685,000) malaria-related deaths estimated for 2010 in 105 countries ([@B111]). The World Health Organization (WHO) defines CM as coma (incapacity to localise a painful stimulus or Blantyre coma score ≤ 2) persisting at least 1 h after termination of a seizure or correction for hypoglycaemia in the presence of asexual *P. falciparum* parasitaemia and without the presence of other causes of encephalopathy ([@B155], [@B143]). However, for practical purposes, any patient presenting with impaired consciousness and falciparum parasitaemia must be started on parenteral antimalarial drugs and transferred to an intensive care unit. Severe malarial anaemia, respiratory distress and hypoglycaemia are the most common concomitant complications in paediatric CM cases ([@B110]), whereas jaundice, acute renal failure and hypoglycaemia are the most frequent concurrent complications occurring in adult CM cases ([@B106], [@B67]). Up to 75% of CM-related deaths occur within 24 h of admission which makes the initiation of antimalarial treatment right after confirmation of malarial parasitaemia a priority over further diagnostic work up ([@B67]). Recent studies showed that intravenous artesunate is superior to intramuscular artemether or intravenous quinine and it is currently recommended as the treatment of choice for CM (2.4 mg/kg bolus on admission, at 12 h and 24 h, thereafter once daily until oral medication can be taken reliably) ([@B42], [@B43]). Despite the efficacy of intravenous artesunate, mortality by severe malaria in general, and by CM in particular, is still high even when clinical trials provide adequate patient care, as observed in the South East Asian Quinine Artesunate Malaria Trial (adults) and Africa Quinine Artesunate Malaria Trial (children)([@B42], [@B43]). In addition, 11% of children surviving CM present gross neurological deficits at discharge (most commonly spasticity, ataxia, hemiplegia, speech disorders and blindness) and up to 25% may sustain long-term cognitive deficits ([@B18], [@B16], [@B27], [@B17], [@B70]). Development of adjuvant therapies is therefore urgently necessary to modify the high rates of mortality and sequelae resulting from CM.

*C* *M pathogenesis: a central role for vascular dysfunction* - The pathogenesis of CM is still poorly understood. The histopathological hallmark of CM is the sequestration of parasitised red blood cells (pRBCs) in the brain of patients that died of CM ([@B117], [@B118]). Quantitative analysis of brain sections in necropsy studies of patients in Thailand and Vietnam showed that CM patients had more sequestered pRBCs in the brain than patients that died of other malaria complications. In addition, pRBC accumulation in the brain of CM patients was also higher than in other vital organs ([@B117], [@B118]). *P. falciparum* pRBCs adhere to endothelial cells through ligand-receptor interactions mediated by a family of variant antigens expressed by the parasites and exported to the surface of the RBC. The *P. falciparum* erythrocyte membrane protein-1 (PfEMP1) is encoded by approximately 60 var-genes in the *P. falciparum* genome, but usually only one variant is expressed at a time by each individual parasite ([@B81], [@B134]). These proteins have characteristic motifs that signal for their export to the RBC membrane, where they accumulate in protuberant structures known as knobs. Different PfEMP1 variants can interact with different receptors in endothelial cells. Several ligands have been identified, among them CD36 ([@B9]), ICAM1 ([@B13], [@B20]), thrombospondin ([@B128]) and chondroitin sulphate ([@B123]). A potential role for ICAM1 in pRBC sequestration in the inflamed endothelium of brain vessels has been described ([@B145], [@B138]) and patients that died of CM showed high expression of ICAM1 in the brain ([@B138]). Inflammation indeed has been linked to sequestration and coagulation as critical factors for CM development (van der Heyde et al. 2006, [@B109]) and recent work has shown that markers of inflammation and endothelial activation such as plasma levels of soluble ICAM1, C-reactive protein and angiopoietin-2 are elevated at hospital admission of children with CM and remain high even after successful treatment with antimalarial drugs ([@B108]). More recently, it was demonstrated that severe malaria and CM are associated with the expression of specific PfEMP1 subtypes containing domain cassette 8 ([@B84], [@B14]), whose binding to endothelial cells is mediated by endothelial protein C receptor, a host receptor involved in anticoagulation and endothelial cytoprotection and quiescence ([@B146]).

Adherence of large numbers of pRBC to the endothelium of brain post-capillary venules would plug the vessels, leading to mechanical occlusion, impaired blood flow with resulting ischaemia and tissue hypoxia ([@B98]). In fact, microvascular congestion and pRBC sequestration were independent predictors of clinical diagnosis of CM ([@B119]). In addition, retinal angiography studies in children with CM showed the frequent occurrence of impaired perfusion, vessel occlusion and filling defects likely due to pRBC sequestration in the retinal microvasculature ([@B11]). Single photon emission computed tomography also indicated the occurrence of marked cerebral hypoperfusion in a CM patient ([@B73], [@B12]). These findings evidence hypoxia and ischaemia as important components in the pathogenesis of CM. Mechanical obstruction of blood flow by adherent pRBCs has long been considered as the central mechanism leading to CM ([@B2], [@B118], [@B153], [@B152]). However, it is becoming increasingly clear that blood vessel function in CM is compromised well beyond occlusion. Spastic constriction of cerebral arterioles has been identified in CM patients ([@B116]). In addition, severe malaria patients show lower reactive hyperaemia-peripheral arterial tonometry (RH-PAT) index (a measurement of reactive vasodilation) than uninfected controls or patients with uncomplicated malaria ([@B158]). The mechanisms behind vasoconstriction and vascular dysfunction in CM are not completely understood, although mediators such as nitric oxide (NO), endothelins and the angiopoietin-Tie2 axis seem to be involved ([@B151], [@B158], [@B157], [@B41], [@B32], [@B93], [@B69]).

*NO in human CM* - NO is a small gaseous molecule with a central role in the maintenance and regulation of vascular tone ([@B68]). NO is generated from the amino acid (aa) L-arginine (L-Arg) by three isoforms of the enzyme NO synthase (NOS). Two of the isoforms are expressed constitutively in endothelial cells \[endothelial NOS (eNOS)\] or in neurons \[neuronal NOS (nNOS)\], whereas inducible NOS (iNOS) is expressed in several cell types, mainly phagocytes, upon stimuli such as a pro-inflammatory cytokines ([@B56]). eNOS is the main isoform regulating vascular tonus systemically, nNOS being also important in the regulation of cerebral blood flow. NO overproduction by iNOS during pathological conditions such as sepsis may cause life-threatening hypotension ([@B15]). In physiological conditions, NO produced by eNOS in endothelial cells diffuses to the neighbouring vascular smooth muscle cells where it activates soluble guanylate cyclase (sGC) that, in turn, generates cyclic guanosine monophosphate (cGMP). cGMP activates protein kinase G, which causes reuptake of Ca++ and the opening of calcium-activated potassium channels. The fall in concentration of Ca++ ensures that the myosin light-chain kinase can no longer phosphorylate the myosin molecule, thereby leading to relaxation of the smooth muscle cell, causing vasodilation and increasing blood flow.

Low NO bioavailability has been described in several haemolytic disorders ([@B129], [@B107]). Haemolysis causes gram quantities of haemoglobin to be released in the bloodstream. Cell-free plasma haemoglobin is a potent scavenger of NO and will deplete most of the NO that is produced by endothelial cells ([@B129]). More recently, it has been shown that RBC microparticles formed during pathological haemolysis also scavenge NO with similar potency to cell-free haemoglobin ([@B88]). In addition, RBC arginase is released in the plasma during haemolysis and will compete with NOS for the same substrate, L-Arg, depleting it ([@B129]). Finally, L-Arg transport across RBC membrane is impaired and arginase-mediated L-Arg consumption enhanced by free plasma haeme released from cell-free haemoglobin ([@B112]). Impaired NO bioavailability represents the central feature of endothelial dysfunction observed in haemolytic disorders ([@B107]). The consequences of impaired NO bioavailability include vasoconstriction, reduced blood flow, impaired reactivity of blood vessels to dilation stimuli, acquisition of a pro-inflammatory, pro-adhesive phenotype by endothelial cells, loss of endothelial cell-cell junctional cohesiveness, among other alterations.

A seminal study in Tanzania showed that plasma and urine levels of nitrite and nitrate (stable metabolites of NO) were inversely correlated with malaria severity in children ([@B4]). This finding was confirmed later in patients with CM who showed decreased plasma and cerebrospinal levels of nitrite and nitrate ([@B44]). In vitro, inhibition of NO production by treatment of human microvascular endothelial cell with the NOS inhibitor L-N(G)-nitro-arginine-methyl-ester (L-NAME) enhanced *P. falciparum* pRBC adhesion, whereas addition of a NO-donor reduced adhesion ([@B137]). Patients with CM showed low levels of L-Arg, the substrate for NO generation by NOS isoforms and hypoargininaemia was significantly associated with CM case-fatality ([@B91]). Severe malaria patients showed endothelial dysfunction characterised by lower levels of exhaled NO and lower reactive RH-PAT index than uninfected controls or patients with moderately severe malaria ([@B158]). Endothelial dysfunction was also associated with elevated blood lactate and measures of haemolysis. Recovery of endothelial function in severe malaria was shown to be associated with recovery from hypoargininaemia and lactic acidosis and the median time to normal endothelial function was 49 h after the start of antimalarial therapy ([@B159]). Cell-free haemoglobin concentrations in patients with severe malaria were significantly higher than in those with moderately severe malaria or controls and were independently associated with lactate, endothelial activation and proinflammatory cytokinaemia ([@B163]). In addition, plasma levels of asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of NOS, were shown to be elevated in adults with severe malaria. ADMA levels were associated with decreased exhaled NO and endothelial function and shown to be an independent predictor of mortality ([@B162]). In children with severe malaria, although ADMA levels were actually low, the L-Arg to ADMA ratio was even lower due to severe hypoargininaemia ([@B150]). Intravenous infusion of L-Arg increased the RH-PAT index and exhaled NO levels in patients with moderately severe malaria ([@B158]) was shown to be safe ([@B157]) and to result in sustained plasma levels of L-Arg ([@B165]). However, in a recent randomised pilot study of intravenous L-Arg infusion in Indonesian adults with severe malaria, no effect on lactate clearance or endothelial NO bioavailability (RH-PAT index) was observed ([@B161]). A clinical trial with inhaled NO in Ugandan children with CM is ongoing ([@B64]).

*Endothelins in human CM* - Endothelins are potent regulators of the vascular tone that also have mitogenic, apoptotic and immunomodulatory properties ([@B130], [@B75], [@B7]). These characteristics make endothelins important regulators of pulmonary and systemic arterial pressure, kidney function, angiogenesis, inflammation and adaptive immune function ([@B7], [@B62], [@B80]). Three isoforms of endothelin have been identified (ET-1, ET-2 and ET-3), all are 21 aa peptides produced by the same metabolic pathways and act through the same receptors ([@B102]). However, each isoform is encoded by a different gene and has a different tissue expression ([@B132]). ET-1 is the best studied, the most abundant and is synthesised by vascular endothelial cells throughout the body as well as by a variety of other cells, including leukocytes, ﬁbroblasts, vascular smooth muscle cells, neurons and astrocytes ([@B148]). Endothelin precursors are called big-endothelins (big-ET-1, big-ET-2 and big-ET-3) which bind to the endothelin receptors with a much lower affinity ([@B65]). All three isoforms of endothelin are synthesised by the cleavage of their precursors by one of the three endothelin converting enzymes (ECE-1, ECE-2 and ECE-3). Once synthesised, endothelins can act through two transmembrane G protein-coupled receptors called endothelin receptor A (ETA) ([@B5]) and B (ETB) ([@B133]). ETA and ETB receptors can have synergetic or opposing effects depending on cell type, tissue type or physiological situation ([@B148]). In addition, the distribution of ETA and ETB receptors varies in each vascular bed and they also can form homo and heterodimers, which increases the complexity of possible responses to endothelins ([@B25], [@B48], [@B148]). For example, ET-1 is classically considered a potent vasoconstrictor acting by increasing intracellular Ca2+ on vascular smooth muscle cells via ETA receptor binding ([@B149]). However, ET-1 can also cause vasodilation by acting via ETB receptors on endothelial cells, which promotes NO release ([@B144]). Hence, the actual knowledge suggests that the effects of endothelins may differ depending on the physiological or pathological situations ([@B7], [@B148]).

ET-1 has been implicated in the pathogenesis of a number of infectious, cardiovascular, cerebrovascular, renal, oncologic, chronic degenerative, inflammatory and auto-immune diseases ([@B45], [@B7], [@B62], [@B80]). Only two human studies analysing ET-1 during malaria infection are available to date ([@B151], [@B41]). They showed that ET-1 and big-ET-1 were increased in the serum of patients with complicated *P. falciparum* malaria when compared with healthy controls. However, except for serum tumour necrosis factor-alpha levels and thrombocytopenia, these studies did not find a correlation between the serum levels of ET-1 or big-ET-1 and disease severity. In vitro studies showed that parasite derived lipid moieties present in the membrane of *P. falciparum*-infected RBCs and haemozoin (malaria pigment) can bind ET-1 ([@B10]). The authors speculate that this unspecific binding could neutralise ET-1 activity by decreasing its bioavailability in the local microenvironment where pRBC sequester. However, the opposite could also be true. pRBC could be a source of ET-1, actually increasing its concentrations and bioavailability in sites of parasite sequestration contributing to the pathogenesis of falciparum complications such as CM. This could also explain the apparent decrease in serum ET-1 levels in patients with severe malaria when compared to uncomplicated malaria patients. These findings indicate that endothelins are involved in CM vascular dysfunction. However, the role of ET-1, ET-2 and ET-3 during human CM needs to be further analysed. ET-3 is of particular interest as it is produced in the brain by endothelial cells and astrocytes and has been shown to cause brain ischaemia and inflammation ([@B46], [@B54], [@B87]).

*A* *ngiopoietin-Tie2 axis in human CM* - Angiopoietin-Tie-2 axis dysfunction is involved in the pathogenesis of several vascular, infectious and oncologic diseases such as breast and lung cancer, hepatocellular carcinoma, atherosclerosis, pre-eclampsia, pulmonary hypertension, thrombosis, vasculitis and infections ([@B1], [@B26], [@B36], [@B40], [@B49]). Angiopoietins (Ang) are \~70 kDa glycoproteins that critically regulate endothelial reactivity to angiogenic and inflammatory factors ([@B51], [@B49]). Four distinct Ang have been described until now: Ang-1, Ang-2, Ang-3 and Ang-4. Ang-1, 3 and 4 are agonists of the receptor Tie-2 (acronym for tyrosine kinase with immunoglobulin and endothelial growth factor homology domains) ([@B37], [@B49]). Ang-2 is a partial/weak agonist of Tie-2 that physiologically acts as a context antagonist of Ang-1 ([@B97], [@B166]). Tie-2 receptors are expressed mainly by endothelial cells, but they are also present in neurons, astroglial cells, pericytes and smooth muscle cells ([@B121]). Ang-1 is incorporated in the extracellular matrix after its release by perivascular cells such as pericytes, vascular smooth muscle cells, platelets and fibroblasts ([@B37], [@B156], [@B105], [@B49]). Ang-1 mediated activation of Tie-2 receptors present on endothelial cells induces endothelial quiescence by inhibiting apoptosis, promoting NO synthesis, increasing the expression of endothelial cell tight junctions and reducing the expression of adhesion molecules such as ICAM-1, VCAM-1 and E-selectin ([@B72], [@B71], [@B79], [@B131]). Therefore, although not formally proven, it is widely believed that continuous Tie-2 activation by Ang-1 maintains vascular quiescence during healthy states ([@B51], [@B49]). Ang-2 is synthesised by endothelial cells and stored inside their specialised granules, Weibel-Palade bodies, for rapid release upon stimulation by angiogenic or inflammatory mediators ([@B53]). As Ang-2 is a weaker partial agonist of Tie-2, in the presence of Ang-1, Ang-2 act mainly as a competitive antagonist inhibiting Tie-2 signalling by displacing Ang-1 from the receptor ([@B166]). Hence, release of Ang-2 destabilises the endothelium via an autocrine mechanism increasing its reactivity to angiogenic and inflammatory stimuli, promoting vascular permeability and up-regulating ICAM-1 and VCAM-1 ([@B97], [@B63], [@B52]). Taken together, these data indicate that the Ang-2/Ang-1 ratio determines the functional status of the vasculature ([@B51]). Physiologically, a low Ang-2/Ang-1 ratio controls vascular responsiveness and keeps endothelium homeostasis. However, following local or systemic endothelial-cell activation, Ang-2 is rapidly released from Weibel-Palade bodies increasing the Ang-2/Ang-1 ratio and the endothelial responsiveness. Ang-3 and Ang-4 are much less studied being orthologous proteins found in mouse and human, respectively ([@B49]). Both Ang-3 and Ang-4 are able to induce angiogenesis in vivo, but their role during inflammation is not understood ([@B85]).

It is well known that endothelial activation is associated with CM development ([@B61]). As Ang are key regulators of endothelial responsiveness, deregulated levels of Ang-1 and Ang-2 systemically or locally in the brain could be involved in the pathogenesis of CM and other falciparum complications. Several human studies showed that decreased Ang-1 and increased Ang-2 levels and elevated Ang-2/Ang-1 ratio are associated with development of severe malaria ([@B160], [@B32], [@B33], [@B31], [@B139], [@B47], [@B94], [@B121]). These alterations in serum Ang-1 and Ang-2 correlate with disease severity, mortality and seem to be particularly more prominent in patients with CM than with other complications of malaria ([@B32], [@B93], [@B69]). In addition, serum levels of Ang-2 and the soluble version of Tie-2 receptor are associated with CM retinopathy in children ([@B33], [@B31]). Increased Ang-2 levels and Ang-2/Ang-1 ratio were shown to be better predictors of disease severity and mortality than Ang-1 in CM, indicating that the increase in endothelium responsiveness during CM may be due to increased Ang-2 rather than decreased Ang-1 levels ([@B32], [@B33], [@B31]). Plasma levels of Ang-2, as well as of soluble ICAM1 and C-reactive protein, remain elevated, even days or weeks after antimalarial treatment, in children admitted with CM, indicating persistent inflammation and endothelial activation ([@B108]).

Deregulation of the angiopoietin-Tie-2 axis, however, is not specific of CM. Increased serum Ang-2 levels are also present during *Plasmodium vivax* infection, a parasite species that classically does not cause severe disease ([@B164], [@B96]). In addition, a recent study with Vietnamese adults failed to show differences in the brain expression of Ang-1, Ang-2 and Tie-2 on endothelial cells, astroglial cells or neurons between CM and non-CM controls presenting confirmed multi-organ dysfunction ([@B121]). Although Ang-1 and Ang-2 expression in neurons was correlated with the incidence of haemorrhages, there was no correlation between the expression of Ang-1, Ang-2 and Tie-2 and pRBC sequestration in the brain. The authors conclude that although angiopoietin-Tie-2 axis dysfunction is related to severity and outcome, it is not a specific event in the brain during CM. These data suggest that disruption of endothelial quiescence seems to be necessary, but not sufficient to cause CM. Several approaches have been used to modulate the systemic levels of Ang-1, Ang-2 and the Ang-2/Ang-1 ratio in murine models of sepsis with some of them showing promising results such as the use of vasculotide, a synthetic agonist of Tie-2 ([@B51]). These approaches could be used in the murine model of CM to reveal the importance of each mediator during the course of the disease and potential adjunctive therapies for CM and severe malaria.

*Experimental models of CM: a way forward to identify mechanisms of vascular dysfunction and evaluate therapeutic interventions* - Studies of CM pathogenesis and therapeutics in humans are subjected to several constraints. Most studies on CM rely on *post-mortem* brain samples, which provide important clues for the understanding of its pathogenesis. Nevertheless, while this material provides evidence of the damage inflicted in fatal cases, it may be deficient in teaching its processes and mechanisms and cannot be compared with patients with more favourable outcomes ([@B89]). In addition, in most cases these samples are obtained from patients that received antimalarial treatment for hours or days and it is hard to measure how the intervention affected the observed alterations. Ocular *fundus* examination allows for the determination some aspects of pathology in live patients being particularly useful for improving the specificity of CM diagnosis ([@B86], [@B154]). Also, it will possibly be valuable as readout for evaluation of potential novel therapeutic interventions. A few magnetic resonance studies have been performed and this is a promising approach to study CM pathogenesis in live patients, however this is an expensive resource largely unavailable in malaria endemic areas and its use may pose some ethical concerns ([@B90], [@B89], [@B120], [@B74]).

There is no animal model that can perfectly mimic human CM. Non-human primate models of CM have been described, for instance a CM-like syndrome occurs in *Macaca mulatta* monkeys infected with *Plasmodium coatneyi* (de [@B39]). However, this and other primate models are largely unavailable for systematic studies and therefore lack extensive characterisation. The best studied animal model for CM is the infection of susceptible mouse strains by the rodent parasite *Plasmodium berghei* ANKA, which induces a fatal neurological syndrome known as experimental CM (ECM) with clinical signs such as ataxia, convulsions, limb paralysis and coma (de [@B38]). The brain of mice with ECM show vascular plugging mainly by adherent leukocytes, diffuse microhaemorrhages, breakdown of the blood brain barrier (BBB) and increased expression of cell adhesion molecules such as ICAM1 ([@B100], [@B24], [@B167]). The relevance of this animal model for the human disease has been heatedly debated recently ([@B28], [@B66], [@B125], [@B127], [@B142], [@B153], [@B83], [@B34]). The main criticism lies on the fact that in human CM the key histological finding is the occlusion of brain post-capillary venules by *P. falciparum* pRBC, whereas in ECM post-capillary venular occlusion is mediated mostly by adherent activated leukocytes. However, leukocytes are found in the brain of CM patients ([@B118]) and pRBC accumulate in the brain of mice with ECM ([@B3], [@B8], [@B57], [@B127]), although the pRBC/leukocyte proportion is different, being higher in human CM. Markers of brain inflammation such as high levels of ICAM-1 expression in the endothelium is observed in both conditions and necessary for sequestration. It has been claimed that adjunctive therapies in ECM are highly effective, contrary to what has been observed in human CM, but in the murine studies the therapies cited as "adjunctive" do not fit this definition ([@B28]). Finally, a large amount of evidence showing several similarities between human and murine CM has not been considered (van der Heyde et al. 2006, de [@B38], [@B66]).

The murine CM model has been instrumental in studying the role of vascular dysfunction in the pathogenesis of CM. Several aspects of vascular pathology have been shown to mimic very closely the findings in the human disease. Contrary to initial hypotheses ([@B29]), studies in this model showed that NO deficiency rather than excess NO production was involved in ECM pathogenesis. Administration of NOS inhibitors such as L-N-monomethyl arginine and N omega-nitro-L-Arg or aminoguanidine L-NAME, even intracranially, did not modify disease outcome ([@B6], [@B82], [@B50]). Mice deficient in either eNOS or iNOS were as susceptible to ECM as wild-type mice and wild-type mice with ECM were shown to display low NO bioavailability, with decreased levels of plasma and brain nitrite/nitrate (stable products of NO), decreased levels of L-Arg (the substrate for NO synthesis by NOS) and decreased brain cGMP levels (the downstream product of NO-stimulated soluble sGC) ([@B60]). Mice with ECM also showed high levels of plasma cell-free haemoglobin, which was shown to scavenge NO and therefore being a major responsible for NO deficiency. Finally, administration of exogenous NO by means of the NO-donor molecule DPTA-NO or by inhaled NO gas to *P. berghei*-infected mice was shown to prevent ECM, decreasing inflammatory and endothelial activation markers and preventing BBB breakdown ([@B60], [@B135]).

In ECM, mRNA expression of ET-1, ECE, ETA and ETB are markedly increased during infection ([@B95], [@B92]). In addition, the pharmacologic blockade of ETA receptors decreased the incidence of haemorrhages in the brain and seemed to increase survival when used in conjunction with artemether to treat mice with CM ([@B35]). High ET-1 levels could be responsible for the intense vasoconstriction and ischaemia that occur in the brain of mice with ECM ([@B76], [@B95], [@B23]). Elevated concentrations of ET-1 also can lead to decreased NO production ([@B122]), increased synthesis of pro-inflammatory mediators by monocytes ([@B140], [@B19]), increased expression of leukocyte adhesion molecules by brain endothelial cells ([@B104]), dysfunction of the platelet anti-aggregating properties of neutrophils ([@B59]) and disruption of the integrity of the BBB ([@B103], [@B124]), alterations that are present in the brain of mice with CM ([@B58], [@B61], [@B126]).

Few studies have explored the role of Ang in ECM. Improved survival in ECM was associated with decreased endothelial activation (increased Ang-1, decreased Ang-2 and soluble ICAM-1) upon preventative treatment of PbA-infected mice with inhaled NO, neuregulin-1 or with compounds that modulate the levels of sphingosine 1-phosphate or in mice deficient for the C5a receptor ([@B55], [@B135], [@B78], [@B141]). Furthermore, PbA-infected mice treated early during infection with artesunate in combination with either inhaled NO or the peroxisome proliferator-activated receptor γ agonist rosiglitazone showed improved survival and cognitive function than mice treated with artesunate plus saline ([@B135], [@B136]). Treatment with rosiglitazone resulted in increased plasma levels and brain expression of Ang-1.

We developed an intravital microscopy methodology for studying in detail the features of cerebral vascular dysfunction and NO deficiency in CM pathogenesis and therapeutics using this mouse model ([@B21]). For this, a chronic closed cranial window is surgically implanted in the mouse's parietal bone allowing access to the pial microcirculation over extended periods of time. *P. berghei* ANKA-infected mice showed marked decreases in cerebral blood flow at the time of ECM manifestation, due to reduced RBC velocities and to widespread cerebral vasoconstriction, similar to the vasospasm phenomenon observed after subarachnoid haemorrhages ([@B23]). The decrease in blood flow associated with decreased haematocrit lead to hypoxia and acidosis, with a marked decrease in oxygen tension in brain arterioles, venules and the perivascular tissue in mice with ECM ([@B22]). Administration of the NO-donor DPTA-NO was able to ameliorate, but not completely prevent the microcirculatory complications of ECM ([@B24], [@B167]). DPTA-NO improved cerebral blood flow mainly by preventing vasoconstriction, with a beneficial effect more pronounced in smaller than in larger arterioles. DPTA-NO also decreased brain vascular inflammation by decreasing the expression of endothelial cell adhesion molecules such as ICAM1 and P-selectin, resulting in decreased leukocyte and platelet adherence and in decreased vascular resistance to blood flow. DPTA-NO treatment also decreased vascular leakage and the incidence of microhaemorrhages. DPTA-NO is a potent NO-donor and in the dose used (1 mg/mouse) it releases large amounts of NO in a short period of time resulting in marked hypotension in normal mice ([@B60]). Therefore, it is useful as a research tool, but has limited potential as a therapeutic intervention. Inhaled NO is an alternative with therapeutic potential and shown to be effective in both preventing ECM as well as an adjunctive therapy with artesunate ([@B60], [@B135]). S-nitrosylated glutathione (GSNO) is a physiological NO-donor and NO reservoir and might have better therapeutic potential. GSNO indeed largely prevented ECM incidence ([@B168]). At higher dose (1 mg/mouse), it even affected parasite growth decreasing parasitaemia and completely preventing ECM incidence. At lower doses it largely prevented ECM incidence without affecting parasitaemia. The higher dose, however, showed a hypotensive effect similar to DPTA-NO, which was not observed with the lower doses. Interestingly, mice with ECM showed marked depletion of brain glutathione levels, indicating increased oxidative stress, but GSNO administration had little or no effect on restoring proper glutathione levels. Other attempted approaches to increase NO bioavailability such as L-Arg and tetrahydrobiopterin (BH4) supplementation with or without arginase inhibition or nitrite administration did not result in protection from ECM, at least in the doses and schemes used ([@B101]).The phosphodiesterase-5 inhibitor sildenafil by itself did not protect from ECM either, however in combination with a lower dose of DPTA-NO (0.1 mg/mouse, also shown to be ineffective in preventing ECM) was able to increase survival of PbA-infected mice with milder effects on blood pressure than the higher dose of DPTA-NO (1 mg/mouse).

Interventions given early during infection, as the approaches described above, are informative about mechanisms of disease and provide evidence on the role of NO and vascular dysfunction in the pathogenesis of the neurological syndrome. However, from these experiments it is not possible to derive information about the therapeutic potential of interventions. This information can be achieved only by testing interventions in late-stage disease in combination with antimalarial drugs such as artemisinin derivatives, the mainstay treatment for CM in humans. A model to test adjuvant therapies for ECM was described in which mice with late-stage ECM, determined by well-defined clinical parameters such as motor scores and degree of hypothermia, were treated with different antimalarial drugs, showing that artesunate and artemether were the most effective in rescuing animals from death ([@B30]). This model has been used to evaluate the efficacy of adjuvant therapies. Administration of the dihydropiridine calcium channel blocker nimodipine, the drug used to prevent vasospasm in sub-arachnoid haemorrhage patients ([@B77]), in combination with artemether improved cerebral blood flow and increased survival of mice with late-stage ECM when compared to artemether alone ([@B23]). An improved nimodipine delivery system using subcutaneous mini-osmotic pumps resulted in efficacy in increasing survival while avoiding deleterious effects on cardiovascular parameters such as heart rate and blood pressure ([@B99]). Similar findings were obtained with glyceryl trinitrate (GTN). GTN is an NO-donor that requires enzymatic transformation in order to release NO. GTN applied to mice with late-stage ECM in the form of transdermal patches increased survival and, despite the high doses needed for its efficacy in rescuing ECM mice, it did not further decrease blood pressure in hypotensive mice. Importantly, transdermal GTN reversed cerebrovascular constriction soon after administration and the effect lasted for the time the patch was applied (24 h), whereas this effect was not observed in mice receiving artemether only ([@B115]). Similarly, inhaled NO in combination with artesunate improved survival of PbA-infected mice compared to artesunate alone ([@B135]). These data show that reversing hypoperfusion by tackling vasoconstriction is a life-saving intervention in ECM and therefore holds potential for translation to the clinical setting.

While directly providing exogenous NO or other vasodilators such as calcium channel blockers constitute a potentially translatable strategy to restore cerebral perfusion during CM, a better understanding of the mechanisms of vascular dysfunction may reveal improved targets for intervention. We have developed a new cranial window procedure allowing implantation of a superfusion chamber to study cerebrovascular functionality in mice with ECM ([@B113]). Using this system, we found that eNOS and nNOS dysfunction are at least partially responsible for the impaired cerebrovascular responses to endothelium-dependent and neuron-dependent vasodilation stimuli ([@B114]). Contrary to normal animals, pial arterioles of mice with ECM did not respond (dilate) to acetylcholine (ACh) (which dilates arterioles via NO production by eNOS) or to N-methyl-D-aspartate (NMDA) (which dilates arterioles via NO production by nNOS). ACh and NMDA induced generation of NO (measured as nitrite/nitrate metabolites) during pial superfusion in normal animals, which was abolished by the NOS inhibitor NG-methyl-L-Arg, but no nitrite/nitrate production was observed upon ACh or NMDA superfusion in mice with ECM. Arteriolar responses were partially restored by adding BH4, an essential cofactor for NOS, to the superfusate, suggesting that BH4 shortage may be implicated in NOS dysfunction. C57BL/6 mice infected with *P. berghei* NK65, which does not induce ECM, showed preserved pial arteriolar responses to ACh and NMDA, indicating that eNOS and nNOS dysfunction is specific for the ECM syndrome. Another important aspect of endothelial dysfunction in ECM is related to the vessel wall shear stress. Mice with ECM show increased expression of iNOS and eNOS. However, total NOS activity is decreased and vascular reactivity to vasodilators is impaired, as described above. Although eNOS expression is increased, eNOS phosphorylation is decreased, indicating deficient stimulation of the endothelium by mechanical forces related to blood flow. Indeed, wall shear stress is decreased in ECM ([@B114]). In addition to resulting in deficient eNOS activation, decreased shear stress favours pRBC and leukocyte adherence to the endothelium and prevents their washout. In patients that die of CM, persistent adherence of pRBC containing dead parasites or pRBC ghosts contributes to persistent vascular occlusion and pathology ([@B118]).

Cerebral hypoperfusion in CM is mainly a consequence of two factors: vascular occlusion and vasoconstriction. These two factors greatly decrease the amount of blood that flows to the brain during CM. Interestingly, although artemether rapidly decreases parasitaemia and vascular occlusion in the first 24 h of treatment of mice with late-stage ECM ([@B30]), it has no effect on arteriolar constriction ([@B115]). Being more persistent than vascular obstruction, vasoconstriction represents a fundamental obstacle to restore perfusion in ECM. Reversing constriction is therefore a key intervention to preserve life in moribund individuals. By reversing constriction, blood flow is increased and oxygen delivery is improved, reversing hypoxia and its consequences such as acidosis. With normal vascular tonus restored, resistance to blood flow decreases and normal shear stress helps washing out adhered cells.
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